Exploring the current and future role of the pharmacists in osteoporosis screening and management in Malaysia

Your article is protected by copyright and all rights are held exclusively by Springer International Publishing AG, part of Springer Nature. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer’s website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".
Exploring the current and future role of the pharmacists in osteoporosis screening and management in Malaysia

L. S. Toh1,2 · P. S. M. Lai3 · S. Othman3 · A. Shah1 · C. P. L. Dang1 · B. Y. Low2 · K. T. Wong2 · C. Anderson4

Received: 17 August 2017 / Accepted: 19 January 2018
© Springer International Publishing AG, part of Springer Nature 2018

Abstract

Background Several studies have found that pharmacists can assist in screening and prevention of osteoporosis by referring patients for bone mineral density scans and counselling on lifestyle changes. In Malaysia, screening osteoporosis in all elderly women is not mandatory due to its cost. One approach to address this gap is to develop a pharmacist-led osteoporosis screening and prevention program. However, there is a paucity of data on the perspectives of Malaysian pharmacists in this area. Objective To explore the perspective of stakeholders (policy makers, doctors, pharmacists, nurses and patients) towards the role of pharmacists in osteoporosis screening and management. Setting A primary care clinic located within a teaching hospital in Kuala Lumpur, Malaysia. Method Patients (n = 20), nurses (n = 10), pharmacists (n = 11), doctors (n = 10) and policy makers (n = 5) were individually interviewed using a semi-structured topic guide. Purposive sampling was used. Interviews were transcribed verbatim and analysed using thematic analysis. Main outcome measure Perspective of stakeholders on the current and future role of pharmacists. Results All participants perceived pharmacists to be suppliers of medication, although there was some recognition of roles in providing medication advice. Nonetheless, these stakeholders were eager for pharmacists to expand their non-dispensing roles towards counselling, creating awareness and screening of osteoporosis. Interviewed pharmacists referred to their current role as ‘robotic dispensers’ and unanimously agreed to spread out to osteoporosis management role. Conclusion Under stakeholders there is a willingness to expand the role of pharmacists in Malaysia to non-dispensing roles, particularly in osteoporosis screening and management.

Keywords Malaysia · Osteoporosis · Pharmacist role · Postmenopausal · Qualitative · Screening

Impact on practice

- This study impacts pharmacy practice as it influences the direction for the Malaysian pharmacist profession. It guides the professions to expand their roles towards non-dispensing roles such as osteoporosis screening and management. Malaysian pharmacist can now explore their integration into osteoporosis screening and management potentially reducing the number of fragility fractures.

Introduction

Osteoporosis inflicts a substantial burden on public health and national economies on the account of fragility fractures that results from the condition [1]. By year 2050, 50% of hip fractures worldwide will occur in Asia [2]. As such, it is
imperative to conduct an intervention for the early detection and treatment of patients at risk [1].

The pharmacy profession has shifted from a product-centred approach to a more patient-oriented approach, which requires more direct interventions and involvement by the pharmacist going beyond medication dispensing [3]. This practice change has led to more intervention by pharmacists [4–7]. There is a growing body of literature supporting the roles of pharmacists in osteoporosis [4–8]. Studies conducted in various settings around the globe have shown that these pharmacists’ interventions improved adherence to osteoporosis medication. Some studies have also reported improvements in both clinical and economic outcome [4–7].

Most pharmaceutical care services are mainly targeted at the treatment of osteoporosis. A further literature search revealed that there are three randomized control trials (RCTs) conducted overseas by community pharmacies to evaluate the impact of pharmacist’s interventions on osteoporosis management [9–11]. However, two of these studies were considered biased [12]. The study by Crockett et al. [10] had a high risk of both selection and information bias as self-reported assessment was used [10, 12]. As for the study by McDonough et al. [11] the study suffered from a high risk of selection bias as the recruitment size and followed up differed between groups [11, 12]. The third study by Yuksel et al. [9] demonstrated low bias in both aspects [9, 12]. Nonetheless, all three studies provided attestation that the intervention of pharmacists increased the number of patients that had their BMD tested and calcium intake initiated, indicating that pharmacists may have a role to play in reducing the gap in osteoporosis management [9–11].

Foundational research on the pharmacist role in osteoporosis screening and management is sparse. Integrating a pharmacist into osteoporosis screening and management is a novel concept and requires a new model of practice to be explored. As such, investigating the perspective of key stakeholders on the pharmacists’ role in osteoporosis screening and management is potentially crucial to the successful implementation of this concept. To date, there have been no studies on a pharmacist-led osteoporosis screening programme in Malaysia. This study explores the perspective of stakeholders such as policy makers, doctors, pharmacists, nurses and patients towards the role of pharmacists in osteoporosis screening and management.

**Aim of the study**

The aim of this study was to explore the perspective of stakeholders such as policy makers, doctors, pharmacists, nurses and patients towards the role of pharmacists in osteoporosis screening and management.

---

**Ethics approval**

Ethical approval was obtained from the University Malaya Medical Centre Ethics Committee (approval number: 914.14).

**Method**

Qualitative, semi-structured in-depth interviews were used to allow for a detailed exploration of the perspective of stakeholders such as patients, nurses, doctors, pharmacists and policy makers on the role of the pharmacists in osteoporosis screening and management.

This study was conducted at the primary care clinics located within a teaching hospital in Malaysia. The data was collected from October 2012 to January 2013. Participants were selected via purposive sampling. Non-osteoporotic postmenopausal women ≥ 50 years of age from three main ethnicity groups (Malays, Chinese, and Indians) in Malaysia were selected to account for any cultural differences. Healthcare professionals (pharmacist, primary care doctors, and nurses) with more than 1 year of working experience at the primary care clinic were selected as they would have sufficient working experience with the primary care clinic system. Policy makers were defined as individuals working in the upper management of the tertiary hospital. This includes head of departments who have an authority to influence and decide to change the practice.

Patients were recruited by approaching them in the primary care clinic while they were waiting for their doctors’ appointment. Patients’ medical records were screened to confirm that they did not have osteoporosis/osteopenia. Healthcare professionals and policy makers were recruited by approaching them personally and setting up appointments for the interviews. The purpose of the study was explained to the participants using written information and consent was obtained.

A topic guide was used to guide the interviews. Three topic guides were developed in English: one for patients, one for healthcare professionals and one for policy makers. The development of the topic guides was based on literature and an expert panel consisting of a consultant endocrinologist and four pharmacists. A translated topic guide was needed as some interviews were conducted in Malay. Forward and backward translation were conducted by two bilingual pharmacists who were not participants of this study. Differences were discussed using the expert panel. Each topic guide was piloted for finalization.

All patients, healthcare professional and policy maker interviews were conducted by the researcher (LST), who
was a pharmacist. However, this was not revealed to the participants until the interview had ended. Interviews lasted an average of 60 min and were conducted by a trained researcher in either English or Malay. All interviews were transcribed verbatim and checked by a second researcher/pharmacist for accuracy. All transcripts were offered to each interviewee to check for accuracy but all declined.

Data analysis

QSR International Pty Ltd. NVivo version 10 for Windows, 2012 was used to aid in the analysis of the data. Analysis began during data collection. At the end of each interview, the researcher wrote memos of interesting topics that were raised in the interview. The data analysis was data-driven.

Thematic analysis was used to analyze the interview data [13, 14]. It involves analyzing the data as a whole to find repeated patterns of meaning [13, 14]. The analysis of the data involved repeatedly reading the transcripts while listening to the audio recording, and emerging topics were coded and constantly compared and contrasted with other transcripts by one researcher developing a coding framework [13].

The ‘one sheet of paper’ (OSOP) analysis as described by Ziebland and McPherson [15] was then used to progress the analysis of the data. Emerging themes were then refocused at a broader level of themes [13]. This involved sorting the themes into broader themes and collating all the relevant coded data extracts within the identified theme. OSOP involved reading through each code and then noting on a piece of paper all issues that were raised and making connections between them [15]. This process allowed identification of deviant cases that did not fit into the emerging story. These deviant cases were then reanalyzed and accounted for in the analysis [16]. Data saturation was reached when no new codes emerged when new participants were recruited into the study [17].

The results were divided into two sections: the current role of the pharmacists and the future role of the pharmacists in osteoporosis screening and management.

The current perceived role of the pharmacists in practice

Pharmacists were principally perceived by participants to be suppliers of medication, although there was some recognition of roles in providing medication safety, medication costing and medication advice (Table 1).

<table>
<thead>
<tr>
<th>Current perceived pharmacists role</th>
<th>Sub themes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suppliers of medication</td>
<td>Dispensing of medications</td>
</tr>
<tr>
<td></td>
<td>Approval of medication supply</td>
</tr>
<tr>
<td>Medication safety</td>
<td>Ensure patients receives the appropriate medications</td>
</tr>
<tr>
<td>Medication advice</td>
<td>Medication advice to patients</td>
</tr>
<tr>
<td>Medication costing</td>
<td>Medication advice to other healthcare professionals</td>
</tr>
<tr>
<td></td>
<td>Budgeting of medication fund</td>
</tr>
</tbody>
</table>

Table 1 Summary of current perceived pharmacists’ role by patients, nurses, doctors, pharmacists and policy makers

Results

Fifty-six participants were interviewed (patients = 20, nurses = 10, pharmacists = 11, doctors = 10 and policymakers = 5). Each interview lasted an average of 60 min. Patients interviewed were 52–72 years of age. Six patients were Malay, six were Indians, and eight were Chinese. All nurses had 4 years or more of working experience. Pharmacists’ work experience ranged from 2 to 4 years, whilst doctors’ work experience ranged from 3 to 4 years.

Most of the interviews were conducted in English, sixteen patients’ interviews, two nurses’ interviews, nine pharmacists’ interviews, and four doctors. Two patient interviews, eight nurses’ interviews, two pharmacist interviews and five interviews with policy makers were conducted in both English and Malay. Two patient interviews were conducted in Malay.

The results were divided into two sections: the current role of the pharmacists and the future role of the pharmacists in osteoporosis screening and management.
Suppliers of medication

Dispensing medications

The supplying of medications by dispensing was seen to be the core duty of the pharmacists. Dispensing was perceived to be an activity where the pharmacists receives a prescription from the patients at the counter and supplies the appropriate medication. If it is a repeated prescription, the pharmacists would set another appointment date for the patients to collect the medication.

“So I take the (medication from the pharmacist for the) first time… (then) they give me another date to, replenish… (my medication in about) six months or one year… appointment. That’s all…” (Patient-16/Female/70 years)

Approval of medication supply

Additionally, the supplying of medications also refers to the pharmacists’ role in the hospital’s Drugs and Therapeutics sub-committee whereby policies about medication usage are determined. Various policies are approved to only allow certain group of specialist to prescribe certain medications. For example, osteoporosis medications can only be dispensed if a bone mineral densitometry (BMD) scan indicates osteoporosis and if it is prescribed by endocrinologists, orthopaedics and gynaecologists. Therefore, the pharmacists would need to ensure the appropriate forms and procedures are conducted before the medication can be dispensed to the patients.

“So the pharmacists will assess if the patients can get the medication for free, whether the doctor can prescribe the medication or not. Because previously, Fosamax we had to attach the BMD report.” (Nurse-9/Female/42 years)

Medication safety

Ensure patients receives the appropriate medication

The pharmacists were seen to be the final safety net before the patients take home their medications. As the primary care clinic has a lot of trainee doctors, the pharmacists’ role to ensure that the patients receive the appropriate medication is crucial. To elaborate on this, the pharmacists play an important role to check the appropriateness of the medication in terms of the indication, dose and interaction.

 “… At the moment the role… (is) making sure that… the med(ication), the patient is receiving is safe… The main focus is safety… whatever prescription that come in… (we ensure the) dose, the combination of products… is safe for the patient(s)...” (Pharmacist-8/Female/29 years)

Medication advice

Medication advice to patients

The pharmacists were also recognised for their role in giving medication advice. The pharmacists would dispense the medications and provide information to the patients regarding the medications. The information provided includes the indication, mode of action, side effects and method of taking the medications. The monitoring of the patients adherence and compliance is also part of this process. There were some patients who recognized the pharmacists’ role in advice for minor ailments and supplements.

“Pharmacist, I think it’s very important… the role would be to explain to the patients regarding the indication of the medication, the mode of action and the proper way of taking the medications.” (Doctor-3/Female/36 years)

Medication advice to other healthcare professionals

Apart from that, pharmacists were seen by the other healthcare professionals such as doctors and nurses to be medication experts. They would seek advice from the pharmacists regarding: side effects, interactions, dosage, approval to prescribe and availability. However; this is not a common occurrence.

“But for me… the pharmacist relationship is… just to ask about the drugs side effects, the drugs whether (it) can be prescribe, about the dosage, everything…” (Doctor-8/Female/29 years)

Medication costing

Budgeting of medication fund

Pharmacists were seen to be involved in medication costing via the hospital’s Drugs and Therapeutics sub-committee. The policy to only allow certain groups of specialist to prescribe certain medications is part of fund management. Due to the shortage of funds there was a shortage of medications. Hence, pharmacists at the upper management level would need to develop policies to ensure sufficient medication is available where else pharmacists at the frontline would need to ensure these policies are adhered too.
“(This policy is to) save cost because we have to ensure that the usage of the medication is not too high. Hence, we limited it to a certain amount of patients (whom are under the specialists’ care). Therefore, we are forced to do screening of prescribed medication this way.” (Policy maker-5/Male/44 years)

The perceived future role of the pharmacists in osteoporosis screening and management

Doctors, nurses, patients, policy makers and pharmacists themselves were eager for pharmacists to expand their role beyond medication: supply, advice, costing and safety. The stakeholders perceived that the pharmacists should expand their role in terms of counselling, creating awareness and screening of osteoporosis (Table 2).

“But I think we are actually well position to actually do… this screening and in fact to do the counsel(ing) and educating the public.” (Policy maker-2/ Female/51 years)

Counselling

Counselling was seen to be conducting activities such as the current medication therapy adherence and compliance (MTAC) clinic conducted for diabetic patients. This was an individualized service provided by the pharmacists. Pharmacists assist the patients in adjusting their insulin dose and give lifestyle advice. Recommendations to doctor regarding therapy were also given if necessary. However, this service is only conducted for diabetics and patients on warfarin. Therefore, stakeholders noted the possibility of this kind of services to be extended to osteoporosis and other diseases. Additionally, group counselling by the pharmacists was also suggested.

“I want the MTAC [clinic for] osteoporosis to be implemented again in our hospital after proper planning… because… from here we can… reach out to the public because… my daily job. I think (it) is very… difficult for me to actually talk to them (patients).” (Pharmacist-10/ Female/28 years)

Creating awareness of osteoporosis

The second area suggested was creating awareness on osteoporosis and public health in general. Stakeholders suggest various ways such as creating posters, campaigns or giving health talks during clinic session. However, this could also be done opportunistically. For example, pharmacists could casually mention to a postmenopausal women if she has undergone a BMD scan. Pharmacists were seen to be most accessible to patients at the community level. Therefore, pharmacists are in an ideal position to create awareness on osteoporosis and various diseases.

“I think they (primary care pharmacists) have (a) big role because… they are more… involved with community… they have a major role in screening, not only osteoporosis, other diseases as well. And then to educate patients also, they have… a big role.” (Doctor-5/ Male/30 years)

Screening of osteoporosis

Lastly, the pharmacists were seen to be in an ideal position to screen for osteoporosis. This is because pharmacists were seen to be more accessible. Patients would visit the pharmacists several times before their next doctor’s appointment for their repeat prescriptions. This gives the pharmacists the opportunity to tap into screening and prevention of osteoporosis. Patients also perceived pharmacists to be knowledgeable and trust pharmacist for advice.

“Pharmacist can explain to us… rheumatism (referring to osteoporosis)... what you (kind of supplements to) take… we…. trust the pharmacist.” (Patient-6/ Female/72 years)

Currently, both the doctors and nurses are unable to screen for osteoporosis systematically due to the time constraint. If pharmacists were involved in osteoporosis screening it was seen as an improvement to the healthcare system. This facilitates the healthcare professionals to understand each others’ scope of practice better leading to a more effective healthcare system. Additionally, the involvement of pharmacists in osteoporosis screening would lighten the workload of doctors and nurses. This in turn saves both the patients and healthcare professionals’ time. The pharmacist would screen for osteoporosis and the doctors would focus on diagnosis and treatment. Hence, the pharmacists could play a part in osteoporosis screening alerting the doctors when a BMD scan may be needed. This will assists in detecting untreated osteoporosis.

“…Pharmacist can help to save (the) doctor’s time… because some patient(s) (do not) need to (be) referred (to the) doctor. Waste both… (the) doctors’ and
patients’ time… So if (the) pharmacists can do that (osteoporosis screening), it’s good.” (Pharmacist-2/ Female/24 years)

Interviewed pharmacists referred to their current role as ‘robotic dispensers’ and unanimously agreed for an expansion of the pharmacist role in osteoporosis screening. They felt that they weren’t contributing enough to the society and were not satisfied with their current job scope. Therefore, there is a need to expand the pharmacist non-dispensing role in osteoporosis screening.

“(We) dispense like (a) robot… you just push, push, push the thing (medication) out.”
(Pharmacist-6/Female/27 years)

Lastly, all the participants concurred that the expansion of the non-dispensing role of the pharmacists to osteoporosis screening was seen as progression for the profession. The pharmacists’ skills were considered underutilized and shifting from a more medication-centred approach to a more patient-orientated approach was suggested. This emphasizes the need to expand the pharmacists’ role to osteoporosis screening. Additionally, pharmacists were well equipped with the knowledge on the disease, treatment and prevention. Stakeholders noted the success of pharmacists’ independent prescribing role overseas such as in the UK. They unanimously agreed that the pharmacists’ role should be expanded to osteoporosis management.

“(The pharmacists’) job scope is expanding all this time… I wouldn’t be surprised if pharmacist (start) screening (for osteoporosis) since (there are) all ready… pharmacist prescribers (overseas)…” (Pharmacist-11/Female/28 years)

Discussion

The semi-structured interviews outlined above gives us a unique insight into the opinions and views of policy makers, doctors, pharmacist, nurses and patients around the current role of pharmacist in Malaysia and perspective of their future role in osteoporosis management. These stakeholders perceived the current pharmacist role to be medication centred: medication supplier, medication advice, medication safety and medication costing. However, the doctors, nurses, patients, policy makers and pharmacists themselves were eager for pharmacists to expand their role beyond medication to more patient centred such as counselling, creating awareness and screening of osteoporosis.

This concurs with the general progress of the pharmacy profession where the traditional role of pharmacists such as dispensing and compounding of medication shifts to a strengthening role of providing medication information as well as improving the quality use of medication activities such as medication management reviews and chronic disease management programs [19]. In Australia, pharmacists are viewed as highly trained yet underutilised and there is growing support to expand the role of pharmacist within the primary health care sector [20]. Similarly, the stakeholders cited that pharmacists were seen to be more accessible to screen for osteoporosis and that they were underutilized.

Recent research on the expansion of the pharmacist role has shown positive response from general practitioners recognizing the potential benefit of integrating a pharmacist into the medical team with the recognised benefits perceived by the general practitioners increasing over time [21–23]. A systematic review in 2014, revealed that pharmacist collocated in general practice clinics could deliver favourable results when conducting chronic disease clinics and quality of the medicines reviews, resulting in improved clinical outcomes such as blood pressure, blood sugar and cholesterol reduction [24]. Research also found that patients are generally supportive of a pharmacist involvement in non-dispensing roles [25].

Our study noted that one of the pharmacist future role could be to create awareness of osteoporosis. This was a similar finding from another Malaysian study exploring community pharmacist role in type two diabetes management. However, creating awareness of diabetes was a role that the pharmacist was currently conducting [26]. As such, there is a potential for pharmacists to create awareness in osteoporosis as well as other chronic diseases such as diabetes.

Additionally, our study also found that Malaysian pharmacists were minimally involved in osteoporosis management. These findings were similar to another Malaysian study in community pharmacists where the pharmacists appeared to be rooted in the traditional role of medication dispensing but recognizing the potential to expand their roles. In that study, only ad-hoc counselling, such as advice on osteoporosis prevention, risk factors and lifestyle medication was practiced [27]. Our interviewed pharmacists referred to their current role as ‘robotic dispensers’ and unanimously agreed for an expansion of the pharmacist role in osteoporosis screening. The themes from this study resonates with the themes that emerged from other studies. The Canadian survey reported that although pharmacists spend most of their time on dispensing duties but over 60% believed that the time had come to expand their role in areas such as disease prevention and health promotion [28].

The interpretation of the results may be limited to the confined area where the participants were recruited. As such, this qualitative research was then able to reflect on the local setting and are not generalizable to other setting. Nonetheless, the themes generated resonated with themes that occurred in other studies. Another limitation of the study is that the interviews were only conducted in Malay
or English, which are the two main languages, spoken in Malaysia. Interviews were not conducted in Mandarin or Tamil, as those proficient in Mandarin or Tamil would also be able to speak in English or Malay. Although, the data was not analysed independently by two researchers, sections of the coded transcripts were presented to two researchers on separate occasions to establish if other members of the research team agreed with the themes assigned. Discussions were conducted until a consensus was reached. Additionally, the healthcare professionals had varying years of working experiences ranging from 2 to 4 years for doctors and pharmacists and more than 4 years for nurses. However, their views towards the pharmacists role were similar.

The strength of this study is that the sample comprised of a purposive sample of healthcare professionals and consumers involved in the primary care setting. Hence, we were able to gain an in depth understanding of the perceived current and future role of the pharmacist in osteoporosis screening and management. Another strength of this study is that it used qualitative methods to contribute to the currently sparse literature on stakeholders’ perception towards the pharmacists’ role in osteoporosis screening and management. The findings from this study has the potential to highlight the successful integration of the non-dispensing role of the pharmacist in osteoporosis screening and management through an understanding of the current position of the pharmacist and the expected direction of the pharmacy profession. Future studies should focus on developing and integrating the non-dispensing pharmacist role into daily clinical practice and then assessing for effectiveness.

**Conclusion**

Although the current role of pharmacists in Malaysia is medication-centred, healthcare professionals and consumers are willing to expand it to non-dispensing roles, in particular to osteoporosis screening and management. This encourages further efforts to examine the potentially missed opportunities for Malaysian pharmacist to assume an expanded role in health care.

**Funding** Ministry of Science, Technology and Innovation (MOSTI) fund (06-02-12-SF0183).

**Conflicts of interest** All the Authors declares that they have no conflict of interests.

**References**

22. Blondal AB, Jonsson JS, Sporrong SK, Almansdottr AB. General practitioners’ perceptions of the current status and pharmacists’